RM 1995
Alternative Names: RM-1995Latest Information Update: 14 Aug 2023
At a glance
- Originator Aspyrian Therapeutics
- Developer Rakuten Medical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours; Squamous cell cancer
- Preclinical Cancer
Most Recent Events
- 10 Aug 2023 Rakuten Medical and Hikma Pharmaceuticals enters into a marketing agreement to commercialize in Middle East and North Africa
- 02 Aug 2023 Phase-I clinical trials in Solid tumours in Japan (unspecified route)
- 26 Jun 2023 Preclinical trials in Cancer in USA (Parenteral) (Rakuten Medical pipeline, June 2023)